Bryan A. Bernat, Ph.D.

Bryan has 25+ years of industrial experience encompassing a Silicon Valley start-up, small biotech and large pharma.  His experience spans the entire pharmaceutical development spectrum—from drug discovery and candidate selection to pre-clinical IND-enabling studies, clinical trials, FDA approval, commercial launch, and lifecycle management. Bryan’s expertise includes peptides, biologics, small molecules, and nanoparticles.  He designed analytical strategies for synthetic peptides and biosimilars and formulation/analytical plans for early-stage product concepts with novel container closure systems.  His contributions entail crafting analytical strategies, high-level product characterization, formulation design, drug product process scale-up, technology transfer, contract manufacturing, combination products, API sourcing, sterile injectables and regulatory submissions.  Bryan has been integral to the development of 9 commercialized medicines that improve the lives of patients with cancer, neutropenia, cardiovascular disease, hepatitis C, and chronic kidney disease. Most recently, Bryan led teams completing formulation design, analytical development, and technology transfer for Pfizer for an injectable anti-viral to treat COVID-19 and a nasal spray for acute migraine (ZavzpretTM). Previously, Bryan was a key contributor at Array BioPharma and CV Therapeutics and completed postdoctoral studies in Biophysics at the University of Chicago.  Bryan received his Ph.D. in Biochemistry from Vanderbilt University and a B.S. in Biology from Indiana University-Bloomington.